The Novartis drug Zometa® (zoledronic acid for injection) is effective for the treatment of potentially debilitating skeletal related events from bone metastases in prostate cancer patients according to data being presented at the 97th annual meeting of the American Urological Association (AUA) in Orlando, Florida.
Patients with advanced prostate cancer are at high risk for developing bone complications — or skeletal related events (SREs) — which include bone pain, pathologic fractures, need for radiation or surgery to bone and spinal cord compression.
This study marks the first time a bisphosphonate has demonstrated efficacy in treating bone metastases in this patient population. Further, Zometa offers patients, nurses and clinicians a convenient 4 mg (in 100 ml of solution), 15-minute infusion time. “Bone metastases can result in debilitating pain, fractures and compression of the spine and are a significant problem for patients with advanced prostate cancer.
Until now, there were few effective therapies available for these patients,” said Fred Saad, MD, Associate Professor of Urology and Director of Urologic Oncology at the Montreal Cancer Institute, University of Montreal. “Zometa represents a significant advance in the overall treatment of advanced prostate cancer patients and should be a welcome addition for urologists and oncologists in the care of their patients.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!